Related
NEW DELHI: Dr Reddy’s Laboratories was the only oasis in a deserted Dalal Street on Monday as the stock surged over 7 per cent thanks to emergency approval of Sputnik V vaccine in India.
On NSE, the stock ended up 7.09 per cent at Rs 5,098. On BSE, it rose 4.83 per cent and was the only gainer among Sensex stocks.
The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) on Monday took up the application of Dr Reddy's Laboratories seeking emergency use authorisation for Sputnik V.
The Drugs Controller General of India (DCGI) will take a final call on the recommendation. If approved, it will be the third COVID-19 vaccine to be available in India.
The vaccine would be imported from Russia for emergency use in the country, they said.
In September last year, Dr Reddy's partnered with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V and for its distribution rights in India.
On NSE, the stock ended up 7.09 per cent at Rs 5,098. On BSE, it rose 4.83 per cent and was the only gainer among Sensex stocks.
The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) on Monday took up the application of Dr Reddy's Laboratories seeking emergency use authorisation for Sputnik V.
The Drugs Controller General of India (DCGI) will take a final call on the recommendation. If approved, it will be the third COVID-19 vaccine to be available in India.
The vaccine would be imported from Russia for emergency use in the country, they said.
In September last year, Dr Reddy's partnered with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of Sputnik V and for its distribution rights in India.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.